 |
|
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn
Clin Mol Hepatol. 2020;26(3):352-363. Published online 2020 May 28 DOI: https://doi.org/10.3350/cmh.2019.0044n
|
|
Citations to this article as recorded by
 Study on the intestinal permeability of lamivudine using Caco-2 cells monolayer and Single-pass intestinal perfusion
Weiyin Huang, Shuang Chen, Lin Sun, Hubin Wwang, Hongqun Qiao
Saudi Journal of Biological Sciences.2022; 29(4): 2247. CrossRef External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Cancers.2022; 14(3): 711. CrossRef
|